CLINICAL_TRIALS
trial_result
· 2014-03-28
Clinical Trial Update: Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated [Phase 1]
Summary
Phase 1 trial update of TRC105 with standard-dose bevacizumab in adults with solid tumors indicated for bevacizumab.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tracon Pharmaceuticals Inc. | Conditions: Adult Solid Tumor | Phase 1 | Status: COMPLETED | Results posted: 2014-03-28